Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Head and Neck CancerLung CancerSarcomaProstate CancerBreast CancerColorectal CancerKidney CancerOvarian CancerPancreatic Cancer
- Interventions
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 17
- Registration Number
- NCT00620295
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Reduced Intensity Hematopoietic Cell Transplantation for Patients With Resistant Langerhans Cell Histiocytosis
Phase 2
Terminated
- Conditions
- Histiocytosis, Langerhans-cell
- Interventions
- Biological: alemtuzumabProcedure: stem cell transplantation
- First Posted Date
- 2008-02-20
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 1
- Registration Number
- NCT00618540
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Bronchial Artery Infusion of Gemcitabine in Treating Patients With Recurrent or Progressive Non-Small Cell Lung Cancer
- First Posted Date
- 2008-02-20
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 4
- Registration Number
- NCT00619021
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12 in Treating Patients With Advanced Leukemia
Phase 1
Terminated
- Conditions
- LeukemiaMyelodysplastic Syndromes
- Interventions
- Biological: anti-CD45 monoclonal antibody AHN-12Radiation: yttrium Y 90 anti-CD45 monoclonal antibody AHN-12
- First Posted Date
- 2008-02-20
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 4
- Registration Number
- NCT00618696
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
Phase 2
Terminated
- Conditions
- Cancer
- Interventions
- Biological: anti-thymocyte globulinBiological: rituximabProcedure: stem cell transplantation
- First Posted Date
- 2008-02-18
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 12
- Registration Number
- NCT00617929
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial Cancer
- First Posted Date
- 2008-02-15
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 26
- Registration Number
- NCT00617188
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Phase 2
Completed
- Conditions
- LeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm
- Interventions
- First Posted Date
- 2008-02-12
- Last Posted Date
- 2020-12-09
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 6
- Registration Number
- NCT00612716
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
CerviPrep for Applying Topical Gemcitabine to the Cervix in Treating Patients With Primary Endometrial, Cervical, or Ovarian Epithelial Cancer
Phase 2
Completed
- Conditions
- Endometrial CancerCervical CancerOvarian Cancer
- Interventions
- Procedure: therapeutic conventional surgery
- First Posted Date
- 2008-02-08
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 18
- Registration Number
- NCT00610740
- Locations
- 🇺🇸
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation
Phase 1
Terminated
- Conditions
- Leukemia
- Interventions
- Procedure: allogeneic bone marrow transplantationProcedure: umbilical cord blood transplantationDrug: Cis-Retinoic acid
- First Posted Date
- 2008-02-07
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 1
- Registration Number
- NCT00609739
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant
Phase 2
Terminated
- Conditions
- Breast CancerIron OverloadLeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesNeuroblastomaOvarian Cancer
- Interventions
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 4
- Registration Number
- NCT00602446
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
© Copyright 2025. All Rights Reserved by MedPath